nodes	percent_of_prediction	percent_of_DWPC	metapath
Silodosin—ABCB1—lung cancer	0.265	1	CbGaD
Silodosin—ABCB1—Topotecan—lung cancer	0.0413	0.0864	CbGbCtD
Silodosin—ABCB1—Gefitinib—lung cancer	0.0377	0.079	CbGbCtD
Silodosin—ABCB1—Vinorelbine—lung cancer	0.0291	0.0609	CbGbCtD
Silodosin—CYP3A4—Topotecan—lung cancer	0.0247	0.0518	CbGbCtD
Silodosin—ABCB1—Crizotinib—lung cancer	0.0231	0.0484	CbGbCtD
Silodosin—CYP3A4—Gefitinib—lung cancer	0.0226	0.0473	CbGbCtD
Silodosin—ABCB1—Gemcitabine—lung cancer	0.0226	0.0473	CbGbCtD
Silodosin—ABCB1—Erlotinib—lung cancer	0.0223	0.0467	CbGbCtD
Silodosin—CYP3A4—Teniposide—lung cancer	0.0219	0.0459	CbGbCtD
Silodosin—ABCB1—Paclitaxel—lung cancer	0.0204	0.0428	CbGbCtD
Silodosin—ABCB1—Irinotecan—lung cancer	0.0202	0.0422	CbGbCtD
Silodosin—ABCB1—Vinblastine—lung cancer	0.0179	0.0375	CbGbCtD
Silodosin—CYP3A4—Vinorelbine—lung cancer	0.0174	0.0365	CbGbCtD
Silodosin—ABCB1—Cisplatin—lung cancer	0.0164	0.0344	CbGbCtD
Silodosin—ABCB1—Etoposide—lung cancer	0.0161	0.0338	CbGbCtD
Silodosin—ABCB1—Docetaxel—lung cancer	0.0148	0.0309	CbGbCtD
Silodosin—CYP3A4—Crizotinib—lung cancer	0.0139	0.029	CbGbCtD
Silodosin—CYP3A4—Erlotinib—lung cancer	0.0134	0.028	CbGbCtD
Silodosin—CYP3A4—Paclitaxel—lung cancer	0.0122	0.0256	CbGbCtD
Silodosin—CYP3A4—Irinotecan—lung cancer	0.0121	0.0253	CbGbCtD
Silodosin—ABCB1—Doxorubicin—lung cancer	0.011	0.023	CbGbCtD
Silodosin—CYP3A4—Vinblastine—lung cancer	0.0107	0.0225	CbGbCtD
Silodosin—ABCB1—Methotrexate—lung cancer	0.0107	0.0223	CbGbCtD
Silodosin—CYP3A4—Etoposide—lung cancer	0.00967	0.0202	CbGbCtD
Silodosin—CYP3A4—Docetaxel—lung cancer	0.00885	0.0185	CbGbCtD
Silodosin—CYP3A4—Doxorubicin—lung cancer	0.0066	0.0138	CbGbCtD
Silodosin—Angiopathy—Irinotecan—lung cancer	0.000415	0.00302	CcSEcCtD
Silodosin—Cardiac disorder—Gemcitabine—lung cancer	0.000414	0.00301	CcSEcCtD
Silodosin—Immune system disorder—Irinotecan—lung cancer	0.000413	0.00301	CcSEcCtD
Silodosin—Jaundice—Etoposide—lung cancer	0.000413	0.00301	CcSEcCtD
Silodosin—Breast disorder—Docetaxel—lung cancer	0.000413	0.00301	CcSEcCtD
Silodosin—Mediastinal disorder—Irinotecan—lung cancer	0.000413	0.003	CcSEcCtD
Silodosin—Insomnia—Erlotinib—lung cancer	0.000413	0.003	CcSEcCtD
Silodosin—Nasopharyngitis—Docetaxel—lung cancer	0.000409	0.00298	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.000409	0.00297	CcSEcCtD
Silodosin—Angiopathy—Gemcitabine—lung cancer	0.000405	0.00295	CcSEcCtD
Silodosin—Immune system disorder—Gemcitabine—lung cancer	0.000403	0.00293	CcSEcCtD
Silodosin—Mediastinal disorder—Gemcitabine—lung cancer	0.000402	0.00293	CcSEcCtD
Silodosin—Hepatobiliary disease—Etoposide—lung cancer	0.000401	0.00292	CcSEcCtD
Silodosin—Gastrointestinal disorder—Topotecan—lung cancer	0.000398	0.0029	CcSEcCtD
Silodosin—Gastrointestinal disorder—Erlotinib—lung cancer	0.000394	0.00287	CcSEcCtD
Silodosin—Hepatobiliary disease—Paclitaxel—lung cancer	0.000393	0.00286	CcSEcCtD
Silodosin—Rash—Teniposide—lung cancer	0.000392	0.00285	CcSEcCtD
Silodosin—Dermatitis—Teniposide—lung cancer	0.000392	0.00285	CcSEcCtD
Silodosin—Sinusitis—Paclitaxel—lung cancer	0.00039	0.00284	CcSEcCtD
Silodosin—Headache—Teniposide—lung cancer	0.00039	0.00284	CcSEcCtD
Silodosin—Gastrointestinal pain—Vinblastine—lung cancer	0.000388	0.00282	CcSEcCtD
Silodosin—Nervous system disorder—Vinorelbine—lung cancer	0.000387	0.00282	CcSEcCtD
Silodosin—Cardiac disorder—Cisplatin—lung cancer	0.000386	0.00281	CcSEcCtD
Silodosin—Tachycardia—Vinorelbine—lung cancer	0.000385	0.0028	CcSEcCtD
Silodosin—Skin disorder—Vinorelbine—lung cancer	0.000383	0.00279	CcSEcCtD
Silodosin—Gastrointestinal pain—Topotecan—lung cancer	0.000377	0.00274	CcSEcCtD
Silodosin—Immune system disorder—Cisplatin—lung cancer	0.000375	0.00273	CcSEcCtD
Silodosin—Abdominal pain—Vinblastine—lung cancer	0.000375	0.00273	CcSEcCtD
Silodosin—Mediastinal disorder—Cisplatin—lung cancer	0.000375	0.00273	CcSEcCtD
Silodosin—Gastrointestinal pain—Erlotinib—lung cancer	0.000373	0.00272	CcSEcCtD
Silodosin—Nausea—Teniposide—lung cancer	0.000369	0.00269	CcSEcCtD
Silodosin—Hypotension—Vinorelbine—lung cancer	0.000368	0.00268	CcSEcCtD
Silodosin—Urticaria—Topotecan—lung cancer	0.000366	0.00267	CcSEcCtD
Silodosin—Abdominal pain—Topotecan—lung cancer	0.000364	0.00265	CcSEcCtD
Silodosin—Abdominal pain—Erlotinib—lung cancer	0.000361	0.00262	CcSEcCtD
Silodosin—Syncope—Irinotecan—lung cancer	0.000357	0.0026	CcSEcCtD
Silodosin—Cardiac disorder—Etoposide—lung cancer	0.000353	0.00257	CcSEcCtD
Silodosin—Loss of consciousness—Irinotecan—lung cancer	0.00035	0.00255	CcSEcCtD
Silodosin—Cardiac disorder—Paclitaxel—lung cancer	0.000346	0.00252	CcSEcCtD
Silodosin—Angiopathy—Etoposide—lung cancer	0.000345	0.00251	CcSEcCtD
Silodosin—Immune system disorder—Etoposide—lung cancer	0.000344	0.0025	CcSEcCtD
Silodosin—Jaundice—Docetaxel—lung cancer	0.000344	0.0025	CcSEcCtD
Silodosin—Mediastinal disorder—Etoposide—lung cancer	0.000343	0.0025	CcSEcCtD
Silodosin—Asthenia—Vinblastine—lung cancer	0.00034	0.00248	CcSEcCtD
Silodosin—Gastrointestinal disorder—Vinorelbine—lung cancer	0.00034	0.00248	CcSEcCtD
Silodosin—Angiopathy—Paclitaxel—lung cancer	0.000339	0.00247	CcSEcCtD
Silodosin—Immune system disorder—Paclitaxel—lung cancer	0.000337	0.00245	CcSEcCtD
Silodosin—Mediastinal disorder—Paclitaxel—lung cancer	0.000336	0.00245	CcSEcCtD
Silodosin—Hepatobiliary disease—Docetaxel—lung cancer	0.000333	0.00243	CcSEcCtD
Silodosin—Asthenia—Topotecan—lung cancer	0.000331	0.00241	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000328	0.00239	CcSEcCtD
Silodosin—Asthenia—Erlotinib—lung cancer	0.000327	0.00238	CcSEcCtD
Silodosin—Mental disorder—Paclitaxel—lung cancer	0.000327	0.00238	CcSEcCtD
Silodosin—Hepatic function abnormal—Doxorubicin—lung cancer	0.000327	0.00238	CcSEcCtD
Silodosin—Pruritus—Topotecan—lung cancer	0.000326	0.00237	CcSEcCtD
Silodosin—Diarrhoea—Vinblastine—lung cancer	0.000325	0.00236	CcSEcCtD
Silodosin—Pruritus—Erlotinib—lung cancer	0.000323	0.00235	CcSEcCtD
Silodosin—Gastrointestinal pain—Vinorelbine—lung cancer	0.000322	0.00235	CcSEcCtD
Silodosin—Shock—Irinotecan—lung cancer	0.00032	0.00233	CcSEcCtD
Silodosin—Vascular purpura—Doxorubicin—lung cancer	0.000319	0.00232	CcSEcCtD
Silodosin—Nervous system disorder—Irinotecan—lung cancer	0.000319	0.00232	CcSEcCtD
Silodosin—Diarrhoea—Topotecan—lung cancer	0.000315	0.0023	CcSEcCtD
Silodosin—Dizziness—Vinblastine—lung cancer	0.000314	0.00228	CcSEcCtD
Silodosin—Urticaria—Vinorelbine—lung cancer	0.000313	0.00228	CcSEcCtD
Silodosin—Diarrhoea—Erlotinib—lung cancer	0.000312	0.00227	CcSEcCtD
Silodosin—Abdominal pain—Vinorelbine—lung cancer	0.000312	0.00227	CcSEcCtD
Silodosin—Nervous system disorder—Gemcitabine—lung cancer	0.000311	0.00226	CcSEcCtD
Silodosin—Skin disorder—Gemcitabine—lung cancer	0.000308	0.00224	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000306	0.00223	CcSEcCtD
Silodosin—Dizziness—Topotecan—lung cancer	0.000305	0.00222	CcSEcCtD
Silodosin—Liver function test abnormal—Methotrexate—lung cancer	0.000304	0.00222	CcSEcCtD
Silodosin—Hypotension—Irinotecan—lung cancer	0.000304	0.00221	CcSEcCtD
Silodosin—Dizziness—Erlotinib—lung cancer	0.000302	0.0022	CcSEcCtD
Silodosin—Breast disorder—Methotrexate—lung cancer	0.000298	0.00217	CcSEcCtD
Silodosin—Headache—Vinblastine—lung cancer	0.000297	0.00216	CcSEcCtD
Silodosin—Purpura—Doxorubicin—lung cancer	0.000296	0.00216	CcSEcCtD
Silodosin—Hypotension—Gemcitabine—lung cancer	0.000296	0.00216	CcSEcCtD
Silodosin—Insomnia—Irinotecan—lung cancer	0.000294	0.00214	CcSEcCtD
Silodosin—Cardiac disorder—Docetaxel—lung cancer	0.000294	0.00214	CcSEcCtD
Silodosin—Syncope—Paclitaxel—lung cancer	0.000291	0.00212	CcSEcCtD
Silodosin—Loss of consciousness—Etoposide—lung cancer	0.000291	0.00212	CcSEcCtD
Silodosin—Rash—Topotecan—lung cancer	0.000291	0.00212	CcSEcCtD
Silodosin—Dermatitis—Topotecan—lung cancer	0.00029	0.00211	CcSEcCtD
Silodosin—Nervous system disorder—Cisplatin—lung cancer	0.00029	0.00211	CcSEcCtD
Silodosin—Headache—Topotecan—lung cancer	0.000289	0.0021	CcSEcCtD
Silodosin—Tachycardia—Cisplatin—lung cancer	0.000288	0.0021	CcSEcCtD
Silodosin—Rash—Erlotinib—lung cancer	0.000288	0.00209	CcSEcCtD
Silodosin—Dermatitis—Erlotinib—lung cancer	0.000287	0.00209	CcSEcCtD
Silodosin—Palpitations—Paclitaxel—lung cancer	0.000287	0.00209	CcSEcCtD
Silodosin—Angiopathy—Docetaxel—lung cancer	0.000287	0.00209	CcSEcCtD
Silodosin—Skin disorder—Cisplatin—lung cancer	0.000287	0.00209	CcSEcCtD
Silodosin—Insomnia—Gemcitabine—lung cancer	0.000287	0.00209	CcSEcCtD
Silodosin—Immune system disorder—Docetaxel—lung cancer	0.000286	0.00208	CcSEcCtD
Silodosin—Headache—Erlotinib—lung cancer	0.000286	0.00208	CcSEcCtD
Silodosin—Loss of consciousness—Paclitaxel—lung cancer	0.000286	0.00208	CcSEcCtD
Silodosin—Mediastinal disorder—Docetaxel—lung cancer	0.000285	0.00208	CcSEcCtD
Silodosin—Asthenia—Vinorelbine—lung cancer	0.000283	0.00206	CcSEcCtD
Silodosin—Nausea—Vinblastine—lung cancer	0.000282	0.00205	CcSEcCtD
Silodosin—Gastrointestinal disorder—Irinotecan—lung cancer	0.000281	0.00204	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.00028	0.00204	CcSEcCtD
Silodosin—Pruritus—Vinorelbine—lung cancer	0.000279	0.00203	CcSEcCtD
Silodosin—Mental disorder—Docetaxel—lung cancer	0.000277	0.00202	CcSEcCtD
Silodosin—Hypotension—Cisplatin—lung cancer	0.000276	0.00201	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000275	0.002	CcSEcCtD
Silodosin—Nausea—Topotecan—lung cancer	0.000274	0.00199	CcSEcCtD
Silodosin—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000274	0.00199	CcSEcCtD
Silodosin—Nausea—Erlotinib—lung cancer	0.000271	0.00197	CcSEcCtD
Silodosin—Dry mouth—Paclitaxel—lung cancer	0.000271	0.00197	CcSEcCtD
Silodosin—Diarrhoea—Vinorelbine—lung cancer	0.00027	0.00196	CcSEcCtD
Silodosin—Gastrointestinal pain—Irinotecan—lung cancer	0.000266	0.00194	CcSEcCtD
Silodosin—Tachycardia—Etoposide—lung cancer	0.000264	0.00192	CcSEcCtD
Silodosin—Liver function test abnormal—Doxorubicin—lung cancer	0.000264	0.00192	CcSEcCtD
Silodosin—Skin disorder—Etoposide—lung cancer	0.000263	0.00191	CcSEcCtD
Silodosin—Erectile dysfunction—Methotrexate—lung cancer	0.000262	0.00191	CcSEcCtD
Silodosin—Shock—Paclitaxel—lung cancer	0.000261	0.0019	CcSEcCtD
Silodosin—Dizziness—Vinorelbine—lung cancer	0.000261	0.0019	CcSEcCtD
Silodosin—Orthostatic hypotension—Doxorubicin—lung cancer	0.000261	0.0019	CcSEcCtD
Silodosin—Nervous system disorder—Paclitaxel—lung cancer	0.00026	0.00189	CcSEcCtD
Silodosin—Tachycardia—Paclitaxel—lung cancer	0.000259	0.00188	CcSEcCtD
Silodosin—Breast disorder—Doxorubicin—lung cancer	0.000258	0.00188	CcSEcCtD
Silodosin—Skin disorder—Paclitaxel—lung cancer	0.000258	0.00188	CcSEcCtD
Silodosin—Abdominal pain—Irinotecan—lung cancer	0.000257	0.00187	CcSEcCtD
Silodosin—Nasopharyngitis—Doxorubicin—lung cancer	0.000255	0.00186	CcSEcCtD
Silodosin—Gastrointestinal disorder—Cisplatin—lung cancer	0.000255	0.00186	CcSEcCtD
Silodosin—Hypotension—Etoposide—lung cancer	0.000253	0.00184	CcSEcCtD
Silodosin—Rash—Vinorelbine—lung cancer	0.000249	0.00181	CcSEcCtD
Silodosin—Dermatitis—Vinorelbine—lung cancer	0.000248	0.00181	CcSEcCtD
Silodosin—Hypotension—Paclitaxel—lung cancer	0.000248	0.0018	CcSEcCtD
Silodosin—Headache—Vinorelbine—lung cancer	0.000247	0.0018	CcSEcCtD
Silodosin—Syncope—Docetaxel—lung cancer	0.000247	0.0018	CcSEcCtD
Silodosin—Palpitations—Docetaxel—lung cancer	0.000243	0.00177	CcSEcCtD
Silodosin—Loss of consciousness—Docetaxel—lung cancer	0.000242	0.00176	CcSEcCtD
Silodosin—Hepatobiliary disease—Methotrexate—lung cancer	0.00024	0.00175	CcSEcCtD
Silodosin—Insomnia—Paclitaxel—lung cancer	0.00024	0.00175	CcSEcCtD
Silodosin—Nausea—Vinorelbine—lung cancer	0.000234	0.00171	CcSEcCtD
Silodosin—Gastrointestinal disorder—Etoposide—lung cancer	0.000234	0.0017	CcSEcCtD
Silodosin—Asthenia—Irinotecan—lung cancer	0.000233	0.0017	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000233	0.0017	CcSEcCtD
Silodosin—Dry mouth—Docetaxel—lung cancer	0.000229	0.00167	CcSEcCtD
Silodosin—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000229	0.00167	CcSEcCtD
Silodosin—Asthenia—Gemcitabine—lung cancer	0.000227	0.00165	CcSEcCtD
Silodosin—Pruritus—Gemcitabine—lung cancer	0.000224	0.00163	CcSEcCtD
Silodosin—Diarrhoea—Irinotecan—lung cancer	0.000223	0.00162	CcSEcCtD
Silodosin—Gastrointestinal pain—Etoposide—lung cancer	0.000221	0.00161	CcSEcCtD
Silodosin—Shock—Docetaxel—lung cancer	0.000221	0.00161	CcSEcCtD
Silodosin—Nervous system disorder—Docetaxel—lung cancer	0.00022	0.00161	CcSEcCtD
Silodosin—Tachycardia—Docetaxel—lung cancer	0.000219	0.0016	CcSEcCtD
Silodosin—Skin disorder—Docetaxel—lung cancer	0.000218	0.00159	CcSEcCtD
Silodosin—Gastrointestinal pain—Paclitaxel—lung cancer	0.000217	0.00158	CcSEcCtD
Silodosin—Diarrhoea—Gemcitabine—lung cancer	0.000217	0.00158	CcSEcCtD
Silodosin—Dizziness—Irinotecan—lung cancer	0.000215	0.00157	CcSEcCtD
Silodosin—Urticaria—Etoposide—lung cancer	0.000215	0.00156	CcSEcCtD
Silodosin—Jaundice—Doxorubicin—lung cancer	0.000214	0.00156	CcSEcCtD
Silodosin—Abdominal pain—Etoposide—lung cancer	0.000214	0.00156	CcSEcCtD
Silodosin—Asthenia—Cisplatin—lung cancer	0.000212	0.00154	CcSEcCtD
Silodosin—Cardiac disorder—Methotrexate—lung cancer	0.000212	0.00154	CcSEcCtD
Silodosin—Urticaria—Paclitaxel—lung cancer	0.000211	0.00153	CcSEcCtD
Silodosin—Hypotension—Docetaxel—lung cancer	0.00021	0.00153	CcSEcCtD
Silodosin—Abdominal pain—Paclitaxel—lung cancer	0.00021	0.00153	CcSEcCtD
Silodosin—Hepatobiliary disease—Doxorubicin—lung cancer	0.000208	0.00151	CcSEcCtD
Silodosin—Angiopathy—Methotrexate—lung cancer	0.000207	0.00151	CcSEcCtD
Silodosin—Sinusitis—Doxorubicin—lung cancer	0.000206	0.0015	CcSEcCtD
Silodosin—Immune system disorder—Methotrexate—lung cancer	0.000206	0.0015	CcSEcCtD
Silodosin—Mediastinal disorder—Methotrexate—lung cancer	0.000206	0.0015	CcSEcCtD
Silodosin—Rash—Irinotecan—lung cancer	0.000205	0.00149	CcSEcCtD
Silodosin—Dermatitis—Irinotecan—lung cancer	0.000205	0.00149	CcSEcCtD
Silodosin—Headache—Irinotecan—lung cancer	0.000204	0.00148	CcSEcCtD
Silodosin—Insomnia—Docetaxel—lung cancer	0.000203	0.00148	CcSEcCtD
Silodosin—Diarrhoea—Cisplatin—lung cancer	0.000202	0.00147	CcSEcCtD
Silodosin—Mental disorder—Methotrexate—lung cancer	0.0002	0.00145	CcSEcCtD
Silodosin—Rash—Gemcitabine—lung cancer	0.0002	0.00145	CcSEcCtD
Silodosin—Dermatitis—Gemcitabine—lung cancer	0.0002	0.00145	CcSEcCtD
Silodosin—Headache—Gemcitabine—lung cancer	0.000198	0.00144	CcSEcCtD
Silodosin—Gastrointestinal disorder—Docetaxel—lung cancer	0.000194	0.00141	CcSEcCtD
Silodosin—Asthenia—Etoposide—lung cancer	0.000194	0.00141	CcSEcCtD
Silodosin—Nausea—Irinotecan—lung cancer	0.000193	0.00141	CcSEcCtD
Silodosin—Pruritus—Etoposide—lung cancer	0.000191	0.00139	CcSEcCtD
Silodosin—Asthenia—Paclitaxel—lung cancer	0.00019	0.00139	CcSEcCtD
Silodosin—Nausea—Gemcitabine—lung cancer	0.000188	0.00137	CcSEcCtD
Silodosin—Pruritus—Paclitaxel—lung cancer	0.000188	0.00137	CcSEcCtD
Silodosin—Rash—Cisplatin—lung cancer	0.000186	0.00136	CcSEcCtD
Silodosin—Dermatitis—Cisplatin—lung cancer	0.000186	0.00135	CcSEcCtD
Silodosin—Diarrhoea—Etoposide—lung cancer	0.000185	0.00135	CcSEcCtD
Silodosin—Gastrointestinal pain—Docetaxel—lung cancer	0.000184	0.00134	CcSEcCtD
Silodosin—Cardiac disorder—Doxorubicin—lung cancer	0.000183	0.00133	CcSEcCtD
Silodosin—Diarrhoea—Paclitaxel—lung cancer	0.000181	0.00132	CcSEcCtD
Silodosin—Angiopathy—Doxorubicin—lung cancer	0.000179	0.0013	CcSEcCtD
Silodosin—Dizziness—Etoposide—lung cancer	0.000179	0.0013	CcSEcCtD
Silodosin—Immune system disorder—Doxorubicin—lung cancer	0.000178	0.0013	CcSEcCtD
Silodosin—Mediastinal disorder—Doxorubicin—lung cancer	0.000178	0.0013	CcSEcCtD
Silodosin—Abdominal pain—Docetaxel—lung cancer	0.000178	0.00129	CcSEcCtD
Silodosin—Dizziness—Paclitaxel—lung cancer	0.000175	0.00128	CcSEcCtD
Silodosin—Nausea—Cisplatin—lung cancer	0.000175	0.00128	CcSEcCtD
Silodosin—Mental disorder—Doxorubicin—lung cancer	0.000173	0.00126	CcSEcCtD
Silodosin—Rash—Etoposide—lung cancer	0.000171	0.00124	CcSEcCtD
Silodosin—Dermatitis—Etoposide—lung cancer	0.00017	0.00124	CcSEcCtD
Silodosin—Headache—Etoposide—lung cancer	0.000169	0.00123	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000168	0.00122	CcSEcCtD
Silodosin—Rash—Paclitaxel—lung cancer	0.000167	0.00122	CcSEcCtD
Silodosin—Dermatitis—Paclitaxel—lung cancer	0.000167	0.00122	CcSEcCtD
Silodosin—Headache—Paclitaxel—lung cancer	0.000166	0.00121	CcSEcCtD
Silodosin—Asthenia—Docetaxel—lung cancer	0.000161	0.00117	CcSEcCtD
Silodosin—Nausea—Etoposide—lung cancer	0.000161	0.00117	CcSEcCtD
Silodosin—Pruritus—Docetaxel—lung cancer	0.000159	0.00116	CcSEcCtD
Silodosin—Nervous system disorder—Methotrexate—lung cancer	0.000159	0.00116	CcSEcCtD
Silodosin—Nausea—Paclitaxel—lung cancer	0.000158	0.00115	CcSEcCtD
Silodosin—Skin disorder—Methotrexate—lung cancer	0.000157	0.00115	CcSEcCtD
Silodosin—Syncope—Doxorubicin—lung cancer	0.000154	0.00112	CcSEcCtD
Silodosin—Diarrhoea—Docetaxel—lung cancer	0.000154	0.00112	CcSEcCtD
Silodosin—Palpitations—Doxorubicin—lung cancer	0.000152	0.00111	CcSEcCtD
Silodosin—Hypotension—Methotrexate—lung cancer	0.000151	0.0011	CcSEcCtD
Silodosin—Loss of consciousness—Doxorubicin—lung cancer	0.000151	0.0011	CcSEcCtD
Silodosin—Dizziness—Docetaxel—lung cancer	0.000149	0.00108	CcSEcCtD
Silodosin—Insomnia—Methotrexate—lung cancer	0.000147	0.00107	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000145	0.00106	CcSEcCtD
Silodosin—Dry mouth—Doxorubicin—lung cancer	0.000143	0.00104	CcSEcCtD
Silodosin—Rash—Docetaxel—lung cancer	0.000142	0.00103	CcSEcCtD
Silodosin—Dermatitis—Docetaxel—lung cancer	0.000142	0.00103	CcSEcCtD
Silodosin—Headache—Docetaxel—lung cancer	0.000141	0.00103	CcSEcCtD
Silodosin—Gastrointestinal disorder—Methotrexate—lung cancer	0.00014	0.00102	CcSEcCtD
Silodosin—Shock—Doxorubicin—lung cancer	0.000138	0.001	CcSEcCtD
Silodosin—Nervous system disorder—Doxorubicin—lung cancer	0.000138	0.001	CcSEcCtD
Silodosin—Tachycardia—Doxorubicin—lung cancer	0.000137	0.000997	CcSEcCtD
Silodosin—Skin disorder—Doxorubicin—lung cancer	0.000136	0.000992	CcSEcCtD
Silodosin—Nausea—Docetaxel—lung cancer	0.000134	0.000972	CcSEcCtD
Silodosin—Gastrointestinal pain—Methotrexate—lung cancer	0.000133	0.000965	CcSEcCtD
Silodosin—Hypotension—Doxorubicin—lung cancer	0.000131	0.000954	CcSEcCtD
Silodosin—Urticaria—Methotrexate—lung cancer	0.000129	0.000937	CcSEcCtD
Silodosin—Abdominal pain—Methotrexate—lung cancer	0.000128	0.000933	CcSEcCtD
Silodosin—Insomnia—Doxorubicin—lung cancer	0.000127	0.000924	CcSEcCtD
Silodosin—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000121	0.000882	CcSEcCtD
Silodosin—Asthenia—Methotrexate—lung cancer	0.000116	0.000846	CcSEcCtD
Silodosin—Gastrointestinal pain—Doxorubicin—lung cancer	0.000115	0.000835	CcSEcCtD
Silodosin—Pruritus—Methotrexate—lung cancer	0.000115	0.000835	CcSEcCtD
Silodosin—Urticaria—Doxorubicin—lung cancer	0.000111	0.000811	CcSEcCtD
Silodosin—Abdominal pain—Doxorubicin—lung cancer	0.000111	0.000807	CcSEcCtD
Silodosin—Diarrhoea—Methotrexate—lung cancer	0.000111	0.000807	CcSEcCtD
Silodosin—Dizziness—Methotrexate—lung cancer	0.000107	0.00078	CcSEcCtD
Silodosin—Rash—Methotrexate—lung cancer	0.000102	0.000744	CcSEcCtD
Silodosin—Dermatitis—Methotrexate—lung cancer	0.000102	0.000743	CcSEcCtD
Silodosin—Headache—Methotrexate—lung cancer	0.000102	0.000739	CcSEcCtD
Silodosin—Asthenia—Doxorubicin—lung cancer	0.000101	0.000733	CcSEcCtD
Silodosin—Pruritus—Doxorubicin—lung cancer	9.93e-05	0.000723	CcSEcCtD
Silodosin—Nausea—Methotrexate—lung cancer	9.62e-05	0.000701	CcSEcCtD
Silodosin—Diarrhoea—Doxorubicin—lung cancer	9.6e-05	0.000699	CcSEcCtD
Silodosin—Dizziness—Doxorubicin—lung cancer	9.28e-05	0.000675	CcSEcCtD
Silodosin—Rash—Doxorubicin—lung cancer	8.85e-05	0.000644	CcSEcCtD
Silodosin—Dermatitis—Doxorubicin—lung cancer	8.84e-05	0.000643	CcSEcCtD
Silodosin—Headache—Doxorubicin—lung cancer	8.79e-05	0.00064	CcSEcCtD
Silodosin—Nausea—Doxorubicin—lung cancer	8.33e-05	0.000607	CcSEcCtD
Silodosin—ADRA1D—Signaling Pathways—FGFR1—lung cancer	1.33e-05	0.00011	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IGF1R—lung cancer	1.32e-05	0.00011	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—CXCL8—lung cancer	1.31e-05	0.000109	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—HIF1A—lung cancer	1.31e-05	0.000109	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—FOXO3—lung cancer	1.3e-05	0.000108	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—HES1—lung cancer	1.29e-05	0.000108	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—ENO1—lung cancer	1.29e-05	0.000107	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	1.29e-05	0.000107	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTA3—lung cancer	1.29e-05	0.000107	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—RRM1—lung cancer	1.29e-05	0.000107	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—MAP2K1—lung cancer	1.27e-05	0.000106	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—RAF1—lung cancer	1.27e-05	0.000106	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PIK3CD—lung cancer	1.26e-05	0.000105	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—APOA1—lung cancer	1.26e-05	0.000105	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—IL2—lung cancer	1.25e-05	0.000104	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—KDR—lung cancer	1.25e-05	0.000104	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—PIK3CB—lung cancer	1.24e-05	0.000103	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—AVP—lung cancer	1.21e-05	0.000101	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—PIK3CB—lung cancer	1.21e-05	0.000101	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—B4GALT5—lung cancer	1.21e-05	0.000101	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	1.21e-05	0.0001	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CXCL8—lung cancer	1.19e-05	9.9e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—ERBB3—lung cancer	1.18e-05	9.84e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTA4—lung cancer	1.18e-05	9.8e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IGF1R—lung cancer	1.17e-05	9.73e-05	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CXCL8—lung cancer	1.16e-05	9.69e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CYP2E1—lung cancer	1.16e-05	9.63e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—PTEN—lung cancer	1.16e-05	9.63e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CG—lung cancer	1.15e-05	9.57e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—APC—lung cancer	1.15e-05	9.57e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—KIT—lung cancer	1.15e-05	9.57e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—NRAS—lung cancer	1.15e-05	9.57e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—HES1—lung cancer	1.15e-05	9.56e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTA2—lung cancer	1.15e-05	9.55e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—NQO1—lung cancer	1.14e-05	9.53e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—IL2—lung cancer	1.14e-05	9.46e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—EGF—lung cancer	1.14e-05	9.46e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TERT—lung cancer	1.13e-05	9.43e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—RAF1—lung cancer	1.13e-05	9.37e-05	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—IL2—lung cancer	1.11e-05	9.26e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTA1—lung cancer	1.11e-05	9.21e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—EP300—lung cancer	1.1e-05	9.18e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—MAPK3—lung cancer	1.1e-05	9.17e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—FGFR1—lung cancer	1.1e-05	9.15e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PIK3CB—lung cancer	1.1e-05	9.15e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—POMC—lung cancer	1.09e-05	9.11e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ABCC3—lung cancer	1.09e-05	9.11e-05	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	1.09e-05	9.09e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—HIF1A—lung cancer	1.08e-05	9.02e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—BRAF—lung cancer	1.08e-05	9e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL6R—lung cancer	1.07e-05	8.89e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CREBBP—lung cancer	1.07e-05	8.87e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—AKR1C1—lung cancer	1.06e-05	8.82e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CXCL8—lung cancer	1.06e-05	8.8e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—ERBB3—lung cancer	1.05e-05	8.74e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—EGFR—lung cancer	1.05e-05	8.72e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—APOA1—lung cancer	1.05e-05	8.7e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—KDR—lung cancer	1.04e-05	8.62e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—STK11—lung cancer	1.03e-05	8.59e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—UGT1A1—lung cancer	1.03e-05	8.56e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MAP2K1—lung cancer	1.02e-05	8.47e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CD—lung cancer	1.01e-05	8.41e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—IL2—lung cancer	1.01e-05	8.41e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TERT—lung cancer	1.01e-05	8.37e-05	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—PIK3CA—lung cancer	1e-05	8.33e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GNG11—lung cancer	9.92e-06	8.26e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—KRAS—lung cancer	9.9e-06	8.24e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—FGFR1—lung cancer	9.77e-06	8.13e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—HIF1A—lung cancer	9.62e-06	8.01e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—GSTP1—lung cancer	9.55e-06	7.95e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CG—lung cancer	9.54e-06	7.94e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—APC—lung cancer	9.54e-06	7.94e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—KIT—lung cancer	9.54e-06	7.94e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—NRAS—lung cancer	9.54e-06	7.94e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ALDOA—lung cancer	9.45e-06	7.86e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—EGF—lung cancer	9.43e-06	7.85e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CAT—lung cancer	9.29e-06	7.73e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—APOA1—lung cancer	9.29e-06	7.73e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—KDR—lung cancer	9.2e-06	7.66e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NCOA3—lung cancer	9.17e-06	7.63e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—MAPK3—lung cancer	9.14e-06	7.61e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—PIK3CA—lung cancer	9.09e-06	7.57e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—POMC—lung cancer	9.08e-06	7.56e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MDM2—lung cancer	9.06e-06	7.54e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—RAF1—lung cancer	9.02e-06	7.51e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—BRAF—lung cancer	8.97e-06	7.47e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—ERBB2—lung cancer	8.93e-06	7.43e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ADCY1—lung cancer	8.92e-06	7.43e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ABCG2—lung cancer	8.92e-06	7.43e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—TYMS—lung cancer	8.87e-06	7.39e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL6R—lung cancer	8.86e-06	7.38e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CREBBP—lung cancer	8.85e-06	7.37e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MTOR—lung cancer	8.81e-06	7.33e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CB—lung cancer	8.81e-06	7.33e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—GSTM1—lung cancer	8.77e-06	7.3e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ENO2—lung cancer	8.75e-06	7.28e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—HPGDS—lung cancer	8.75e-06	7.28e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—EGFR—lung cancer	8.69e-06	7.24e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PPP2R1B—lung cancer	8.69e-06	7.24e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTT1—lung cancer	8.48e-06	7.06e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—APC—lung cancer	8.48e-06	7.06e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CG—lung cancer	8.48e-06	7.06e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—KIT—lung cancer	8.48e-06	7.06e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—NRAS—lung cancer	8.48e-06	7.06e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CXCL8—lung cancer	8.47e-06	7.05e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MAP2K1—lung cancer	8.45e-06	7.03e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—HRAS—lung cancer	8.41e-06	7e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CD—lung cancer	8.39e-06	6.98e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP2A6—lung cancer	8.39e-06	6.98e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GCLC—lung cancer	8.39e-06	6.98e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—EGF—lung cancer	8.38e-06	6.97e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CYP1A1—lung cancer	8.32e-06	6.92e-05	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—PIK3CA—lung cancer	8.31e-06	6.92e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—ERCC2—lung cancer	8.25e-06	6.87e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—KRAS—lung cancer	8.21e-06	6.84e-05	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—AKT1—lung cancer	8.18e-06	6.81e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—PIK3CA—lung cancer	8.16e-06	6.79e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—MAPK3—lung cancer	8.12e-06	6.76e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CASP3—lung cancer	8.1e-06	6.75e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL2—lung cancer	8.09e-06	6.74e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—POMC—lung cancer	8.07e-06	6.72e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—IL6—lung cancer	8.05e-06	6.7e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—BRAF—lung cancer	7.97e-06	6.63e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ENO1—lung cancer	7.95e-06	6.62e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCND1—lung cancer	7.89e-06	6.57e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL6R—lung cancer	7.87e-06	6.55e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—JUN—lung cancer	7.87e-06	6.55e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CREBBP—lung cancer	7.86e-06	6.54e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—EGFR—lung cancer	7.72e-06	6.43e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MMP9—lung cancer	7.66e-06	6.37e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CDKN1A—lung cancer	7.63e-06	6.35e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PTEN—lung cancer	7.61e-06	6.34e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—PIK3CA—lung cancer	7.55e-06	6.28e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MDM2—lung cancer	7.52e-06	6.26e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MAP2K1—lung cancer	7.5e-06	6.24e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—RAF1—lung cancer	7.49e-06	6.23e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CD—lung cancer	7.45e-06	6.2e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—AKT1—lung cancer	7.43e-06	6.18e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—ERBB2—lung cancer	7.41e-06	6.17e-05	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—PIK3CA—lung cancer	7.38e-06	6.14e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MTOR—lung cancer	7.31e-06	6.09e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CB—lung cancer	7.31e-06	6.09e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—KRAS—lung cancer	7.3e-06	6.07e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—EP300—lung cancer	7.26e-06	6.04e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—APOA1—lung cancer	7.13e-06	5.94e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP2E1—lung cancer	7.13e-06	5.94e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—SRC—lung cancer	7.06e-06	5.88e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NQO1—lung cancer	7.05e-06	5.87e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CXCL8—lung cancer	7.03e-06	5.85e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—HRAS—lung cancer	6.98e-06	5.81e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—VEGFA—lung cancer	6.88e-06	5.72e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—STAT3—lung cancer	6.81e-06	5.67e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—NRAS—lung cancer	6.79e-06	5.65e-05	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—AKT1—lung cancer	6.79e-06	5.65e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CASP3—lung cancer	6.73e-06	5.6e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL2—lung cancer	6.72e-06	5.59e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	6.7e-06	5.58e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—IL6—lung cancer	6.68e-06	5.56e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MDM2—lung cancer	6.68e-06	5.56e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—AKT1—lung cancer	6.67e-06	5.55e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—RAF1—lung cancer	6.65e-06	5.54e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—ERBB2—lung cancer	6.58e-06	5.48e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCND1—lung cancer	6.55e-06	5.45e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—JUN—lung cancer	6.53e-06	5.44e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CG—lung cancer	6.51e-06	5.42e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MAPK3—lung cancer	6.51e-06	5.41e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MTOR—lung cancer	6.5e-06	5.41e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	6.5e-06	5.41e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MMP9—lung cancer	6.36e-06	5.29e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—STK11—lung cancer	6.36e-06	5.29e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	6.33e-06	5.27e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MYC—lung cancer	6.33e-06	5.27e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PTEN—lung cancer	6.32e-06	5.26e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CXCL8—lung cancer	6.24e-06	5.2e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—HRAS—lung cancer	6.2e-06	5.16e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—POMC—lung cancer	6.2e-06	5.16e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—EGFR—lung cancer	6.19e-06	5.15e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—AKT1—lung cancer	6.16e-06	5.13e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CREBBP—lung cancer	6.04e-06	5.03e-05	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	6.03e-06	5.02e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—EP300—lung cancer	6.03e-06	5.02e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CASP3—lung cancer	5.97e-06	4.97e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL2—lung cancer	5.97e-06	4.97e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—IL6—lung cancer	5.94e-06	4.94e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTP1—lung cancer	5.88e-06	4.9e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—SRC—lung cancer	5.86e-06	4.88e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—KRAS—lung cancer	5.85e-06	4.87e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCND1—lung cancer	5.82e-06	4.84e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—JUN—lung cancer	5.8e-06	4.83e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CD—lung cancer	5.73e-06	4.77e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CAT—lung cancer	5.72e-06	4.76e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—VEGFA—lung cancer	5.71e-06	4.75e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—ALB—lung cancer	5.65e-06	4.71e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—STAT3—lung cancer	5.65e-06	4.7e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MMP9—lung cancer	5.65e-06	4.7e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—NRAS—lung cancer	5.64e-06	4.69e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	5.63e-06	4.68e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PTEN—lung cancer	5.61e-06	4.67e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ABCB1—lung cancer	5.57e-06	4.63e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—AKT1—lung cancer	5.48e-06	4.56e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—TYMS—lung cancer	5.47e-06	4.55e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTM1—lung cancer	5.4e-06	4.5e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MAPK3—lung cancer	5.4e-06	4.49e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	5.37e-06	4.47e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—EP300—lung cancer	5.35e-06	4.46e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MYC—lung cancer	5.25e-06	4.37e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—SRC—lung cancer	5.21e-06	4.33e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TP53—lung cancer	5.2e-06	4.33e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—EGFR—lung cancer	5.14e-06	4.28e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP1A1—lung cancer	5.12e-06	4.26e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ERCC2—lung cancer	5.08e-06	4.23e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—VEGFA—lung cancer	5.07e-06	4.22e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—STAT3—lung cancer	5.02e-06	4.18e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—NRAS—lung cancer	5.01e-06	4.17e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CB—lung cancer	4.99e-06	4.15e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—HRAS—lung cancer	4.97e-06	4.14e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PTGS2—lung cancer	4.95e-06	4.12e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—KRAS—lung cancer	4.85e-06	4.04e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MAPK3—lung cancer	4.8e-06	3.99e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL6—lung cancer	4.76e-06	3.96e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MYC—lung cancer	4.66e-06	3.88e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—EGFR—lung cancer	4.56e-06	3.8e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	4.46e-06	3.71e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—APOA1—lung cancer	4.4e-06	3.66e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—AKT1—lung cancer	4.39e-06	3.65e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PTEN—lung cancer	4.31e-06	3.59e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TP53—lung cancer	4.31e-06	3.59e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—KRAS—lung cancer	4.31e-06	3.59e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—HRAS—lung cancer	4.12e-06	3.43e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—EP300—lung cancer	4.11e-06	3.42e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CG—lung cancer	4.01e-06	3.34e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	3.96e-06	3.3e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL6—lung cancer	3.95e-06	3.29e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TP53—lung cancer	3.83e-06	3.19e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—POMC—lung cancer	3.82e-06	3.18e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CREBBP—lung cancer	3.72e-06	3.1e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—HRAS—lung cancer	3.66e-06	3.05e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—AKT1—lung cancer	3.64e-06	3.03e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CD—lung cancer	3.53e-06	2.94e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL6—lung cancer	3.51e-06	2.92e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ALB—lung cancer	3.48e-06	2.9e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—AKT1—lung cancer	3.23e-06	2.69e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CB—lung cancer	3.07e-06	2.56e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PTGS2—lung cancer	3.05e-06	2.54e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CA—lung cancer	3.04e-06	2.53e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PTEN—lung cancer	2.66e-06	2.21e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—EP300—lung cancer	2.53e-06	2.11e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—AKT1—lung cancer	2.49e-06	2.07e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CA—lung cancer	1.87e-06	1.56e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—AKT1—lung cancer	1.53e-06	1.27e-05	CbGpPWpGaD
